13058_2017_815_MOESM7_ESM.pdf (458.16 kB)
Download file

Additional file 7: Figure S5. of Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

Download (458.16 kB)
journal contribution
posted on 2017-03-06, 05:00 authored by Jessalyn Ubellacker, Marie-Therese Haider, Molly DeCristo, Gloria Allocca, Nicola Brown, Daniel Silver, Ingunn Holen, Sandra McAllister
a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-231 BO2F11 cells with either Matrigel control (green) BMCs from nude mice 5 days after CTL treatment (red) or BMCs from nude mice 5 days after ZOL treatment (blue); n = 12 host mice per cohort, one subcutaneous tumor injection per mouse. Bone marrow obtained from three donor mice per cohort. b Average radiance signal of palpable tumors that grew at each injection site per cohort at experimental endpoint (day (d)14) resulting from admixtures of MDA-MB-231 BO2F11 tumor cells with BMCs from indicated CTL-treated or ZOL-treated donor nude mice. c MDA-MB-231 BO2F11 cells were treated in vitro with indicated doses of ZOL: 3 days later cell toxicity was measured using the CytoTox-Glo Assay. Red arrow indicates ZOL dose that is comparable to in vivo dose (based on estimate of mouse blood volume as 8% of total mouse body weight). (PDF 458 kb)


National Institutes of Health